Abstract 4838
Background
In industrialised countries, about 20% of healthcare spending is currently wasted on ineffective interventions. With growing cancer prevalence and the increasing complexity of care, efficiency must improve – defined as delivering better outcomes to patients for the resources available.
Methods
The All.Can initiative was set up as a multi-stakeholder platform to engage policymakers on the need to remove obsolescence and focus resources on what matters most to patients across the cancer care continuum. Members of the group include patient organisations, policymakers, healthcare professionals, research and industry representatives from across Europe and Canada. All.Can has a continued programme of research and policy engagement to achieve its aims.
Results
The group issued the following policy recommendations: focus care on what matters most to patients; invest in data to evaluate and monitor whether care is delivering optimal outcomes; instil accountability mechanisms across the cancer care pathway, creating a cycle of continuous improvement; and build political to drive meaningful change to systematise good practice. As a starting point however, we need clear definitions of waste and inefficiency from the patient perspective. All.Can will conduct a comprehensive qualitative survey of cancer patients to create a patient-relevant conceptual framework for waste and inefficiency. The survey will also be extended to oncology specialists. Findings will help determine where greatest opportunities lie to improve efficiency in cancer care, and serve as a basis for concrete policy proposals that may make the greatest difference to cancer patients.
Conclusions
Improving efficiency across the entire cancer care pathway is a complex and pressing challenge that will require close collaboration between all stakeholders. The All.Can initiative is a promising way forward.
Clinical trial identification
Not applicable
Legal entity responsible for the study
The Health Policy Partnership Ltd
Funding
Bristol-Myers Squibb, Amgen and MSD
Disclosure
A. Roediger: Employment with MSD. T. Rosvall-Puplett: Employment with Bristol-Myers Squibb. K. Steinmann: Employment with Amgen. S. Wait: Received consultancy fees from Amgen, MSD and Bristol-Myers Squibb (the funders of All.Can) through organisation, the Health Policy Partnership, for providing secretariat to All.Can. All other authors have declared no conflicts of interest.